In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Blood Advances
Eleanor R C FiedlerMichael T Hemann

Abstract

Despite the addition of tyrosine kinase inhibitors (TKIs) to the treatment of patients with BCR-ABL1+ B-cell precursor acute lymphoblastic leukemia (BCR-ABL1+ BCP-ALL), relapse both with and without BCR-ABL1 mutations is a persistent clinical problem. To identify BCR-ABL1-independent genetic mediators of response to the TKI dasatinib, we performed in vivo and in vitro RNA interference (RNAi) screens in a transplantable syngeneic mouse model of BCR-ABL1+ BCP-ALL. By using a novel combination of a longitudinal screen design and independent component analysis of screening data, we identified hairpins that have distinct behavior in different therapeutic contexts as well as in the in vivo vs in vitro settings. In the set of genes whose loss sensitized BCR-ABL1+ BCP-ALL cells to dasatinib, we identified Pafah1b3, which regulates intracellular levels of platelet-activating factor (PAF), as an in vivo-specific mediator of therapeutic response. Pafah1b3 loss significantly sensitized leukemia cells to the multiple TKIs, indicating that inhibition of PAFAH1B3 in combination with TKI treatment may be an effective therapeutic strategy for BCR-ABL1+ BCP-ALL patients. PAF-induced cell death as well as surface levels of PAF receptor (PAFR) in ...Continue Reading

References

Aug 18, 2000·Neural Networks : the Official Journal of the International Neural Network Society·A Hyvärinen, E Oja
Jun 14, 2003·Leukemia & Lymphoma·Yves DenizotFranck Trimoreau
Oct 1, 2004·The Journal of Biological Chemistry·Fanny BoninSteffany A L Bennett
May 17, 2005·Toxicology and Applied Pharmacology·Gary B QuistadJohn E Casida
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Oct 4, 2005·Nature Genetics·Ross A DickinsScott W Lowe
Apr 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·Richard T WilliamsCharles J Sherr
Jul 14, 2006·Leukemia Research·Stéphane ReynaudYves Denizot
Aug 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephan L BrownRicardo M Richardson
Aug 28, 2007·Cancer Metastasis Reviews·Vladislava Melnikova, Menashe Bar-Eli
Sep 1, 2007·Genes & Development·Richard T WilliamsCharles J Sherr
Oct 8, 2008·Journal of Lipid Research·Thomas M McIntyreDiana M Stafforini
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Feb 9, 2011·Journal of Hematology & Oncology·Hilmar QuentmeierHans G Drexler
Mar 31, 2011·Nature Reviews. Clinical Oncology·Claudio TripodoStefano A Pileri
Jun 15, 2011·Expert Review of Hematology·Edward Allan R Sison, Patrick Brown
Aug 16, 2013·Nature·Slobodan BeronjaElaine Fuchs
Oct 26, 2013·Nature Protocols·F Ann RanFeng Zhang
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Sep 6, 2015·Genes & Development·Carman Man-Chung LiTyler Jacks
Nov 21, 2015·Cancer Discovery·Nadya DimitrovaTyler Jacks

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.